felicitex therapeutics inc an oncology drug development company filed for an initial public offering with the us securities and exchange commission on wednesday the company said it is planning to offer 248 million units which are expected to be priced between 4525 and 725 per unit the units will consist of one share of common stock and one warrant to purchase a share of common stock the company said products in its pipeline include fx1610 which is being developed for pediatric leukemia  acute lymphoblastic leukemia an orphan drug indication of high unmet medical need felicitex said it expects to file an investigational new drug application for fx1610 during the first half of next year other products in the pipeline include fx7742 which is being developed for solid tumor indications and fx9847 which is being developed for solid tumor indications as a backup to fx7742 the company said felicitex said it intends to apply to list its shares and warrants on the nasdaq capital market aegis capital corp is listed as the offerings underwriter